Trial
NCT06860386
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
Pembrolizumab
Why stopped
Funding unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-06